UnitedHealth Group Incorporated (UNH · NYSE)

UnitedHealth Group has beaten estimates in each of its last four quarters, most recently reporting Q2 2026 EPS of $6.38 versus $4.94 expected, though quarterly operating income slipped to $7.99B from $8.99B in the prior quarter. Trailing-twelve-month revenue stands at $450.53B with just 0.4% year-over-year growth, while earnings rose 61.5%, and the company carries $73.33B in total debt against $28.59B in cash with $10.25B in quarterly free cash flow. The stock, at $376.59, has fallen 11.2% over three months and trades 13.2% below its 52-week high, with an RSI of 33 and a price 5.2% below its 50-day moving average. The analyst target sits at $481.72, and leverage is moderate at 2.7x debt/EBITDA with a current ratio of 0.78.